Familial hypercholesterolemia (FH) is a common genetic cause of elevated low-density lipoprotein cholesterol (LDL-C) due to defective clearance circulating LDL particles. All FH patients are at high risk for premature cardiovascular disease (CVD) events their genetically determined lifelong exposure LDL-C levels. However, different rates CVD have been reported in patients, even among those with...

The density distribution of electronegative LDL [LDL(-)], a cytotoxic and inflammatory fraction of LDL present in plasma, was studied in 10 normolipemic (NL), 6 FH, and 11 hypertriglyceridemic (HTG) subjects. Six LDL subclasses of increased density (LDL1 to LDL6) were isolated by density-gradient ultracentrifugation (DGU). NL and FH subjects showed prevalence of light LDL, whereas HTG subjects ...

INTRODUCTION: Paraoxonase 1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme which known to hydrolyse most pesticides including organophosphates (OPs) and prevent atherosclerosis by inhibiting oxidative modification of low-density (LDL). Glyphosate one the common organophosphate used in agriculture many developing countries Malaysia. The aim this study assess PON1 ability oxidized L...

Abstract Background Sampson et al. developed a novel method to estimate very low-density lipoprotein cholesterol (VLDL-C) and (LDL-C) in the setting of hypertriglyceridemia. Familial Combined Hyperlipidemia (FCHL) is common primary dyslipidemia which composition interferes with LDL-C estimation. This study aimed evaluate performance using this new (LDL-S) compared estimated by Friedewald’s Mart...

The aim of this work was to investigate the possible mechanisms for uptake by human monocyte-derived macrophages (HMDM) of low density lipoprotein (LDL) pretreated with human arterial chondroitin-6-SO4-rich proteoglycan (LDL-PG). HMDM were incubated with 125I-labeled tyramine cellobiose-labeled LDL-PG, native LDL, and acetylated LDL (Ac-LDL). The results showed that two to four times more LDL-P...

Low-density lipoprotein (LDL) indubitably contributes causally to atherosclerosis, a leading challenge health worldwide. Interventions that lower LDL cholesterol (LDL-C) have made remarkable inroads against this global scourge. Recent therapeutic advances achieved ever levels of LDL-C. Improved cardiovascular outcomes continue accrue from these interventions. In particular, the discovery role p...